Opioid dysregulation in schizophrenia was first suggested in the 1980s21 based on findings of elevated beta-endorphin levels in the cerebrospinal fluid of schizophrenia patients22–24 and clinical studies of naloxone, a MOR antagonist treatment showing a reduction of psychotic symptoms in some patients25. This evidence concerns the gene POMC and schizophrenia.